Projects related to health services research

PMV forschungsgruppe

Evidence based Polypharmacy Program with Implementation into health care (EVITA)

Project leader: Prof. Dr. F. Gerlach, University Frankfurt with consortium partners University Bielefeld, University Cologne (PMV forschungsgruppe), Universität Heidelberg

Contact: Dr. Ingrid Schubert, Dr. Veronika Lappe

Duration: 11/2017 – 10/2020

Funding institution: Innovation Committee of the Federal Joint Committee (G-BA)

Project description:

A generic structured program for patients with multiple chronic diseases developed across indications and from the perspective of patients.

Due to demographic changes, patients with polypharmacy are an increasing vulnerable population with many physician contacts and hospital stays. Besides a higher risk for hospitalization and death, they have a high risk for unwanted drug effects, loss of quality of life and functions. To deliver care as needed and economically does not only mean to avoid over- and misuse of drug prescribing but has also to address underuse of prescribing - especially concerning pain medication as could be demonstrated in own and international studies.

EVITA aims at developing a concept for a structured disease management program targeting patients with chronic diseases and polypharmacy. The concept will based on the evidence synthesis, both needs and health economic analyses and encompass an update of the general practitioners’ guideline “Multimedication”. Besides, the project aims to transfer knowledge into the vocational training and further education of physicians and pharmacists, The project receives funding from the Federal Joint Committee (G-BA) - Innovation Fund, Grant agreement number 01VSF16034)


Dent@Prevent

Project leader: Prof. Dr. Dr. S. Listl, University Heidelberg with consortium partners University Köln (PMV forschungsgruppe), University hospital Heidelberg, SpektrumK GmbH, HRI - Health Risk Institute GmbH, University hospital Köln

Contact: Ingo Meyer

Duration: 05/2017 – 04/2020

Funding institution: Innovation Committee of the Federal Joint Committee (G-BA)

Project description:

The project Dent@Prevent aims at improving quality and efficiency of care for patients with oral and general chronic conditions. This is addressed via examining the links between the various disease processes, development of a mobile computing app for collecting Patient Reported Outcome Measures (PROMs), and piloting of an electronic Decision Support System. The project will integrate routinely collected administrative data and PROMs to support better evidence-informed and inter-sectoral decision making.

Studies indicate the existence of common risk factors for chronic pathologies and other chronic diseases. This correlation is particularly noticeable at periodontitis, diabetes and coronary heart disease. Dent@Prevent aims to improve the cooperation between the medical staff both inside and outside the dentistry. The objective is to ensure that doctors and patients are equally informed and can decide together about further treatment.

Firstly, it will be investigated how and why dental- and chronic-systemic diseases are related. To achieve this, scientific articles are systematically analysed and anonymised data from statutory health insurances analysed. Simultaneously, a smartphone app is developed with which the treatment decision can be more strongly targeted to the individual patient: With the app, patients can, for example, provide individual information about their health with regard to their oral health and general health.

Together with the results of the literature research and the analysis of the health insurance data, these reports are used for the development of a digital decision support tool. The insights gained during the project on the interrelationship of dental and systemic diseases can be incorporated into the training and further education of (dentists) physicians.

In the case of success, the developed app and the digital tool can be adapted and used for decision support in other areas.

Dent@Prevent receives funding from the Federal Joint Committee (G-BA) - Innovation Fund, Grant agreement number: 01VSF16052

https://www.oralsystemicintegration.com/


AdAM (Application for Digitally Supported Pharmacotherapy Management)

Project leader: Frau P. Kellermann-Mühlhoff (BARMER-GEK) with consortium partners Kassenärztliche Vereinigung Westfalen-Lippe, University Frankfurt, University Bielefeld, University Cologne (PMV forschungsgruppe), University Bochum, University hospital Cologne

Contact: Peter Ihle

Duration: 01/2017 – 12/2019

Funding institution: Innovation Committee of the Federal Joint Committee (G-BA)

Project description:

Many elderly people suffer from multimorbidity and require several drugs simultaneously. The medical treatment of these patients brings with it an increased risk of drug interaction, side effects and medication errors. AdAM contains specially developed software, which offers physicians digital support to improve the quality, safety and coordination of pharmacotherapy and healthcare management. The software has various functions, such as: 1) Extracting treatment-relevant patient information from health insurance carrier routine data in real time with the patient’s informed consent 2) Conducting electronically supported drug safety tests and printing the required standard German drug charts in various languages for patients 3) Sending automatic risk warnings in the event of medication errors 4) Automatic notifications when outpatients are admitted for inpatient treatment and coordinating drug administration with the hospital Evaluation should point out to what extend hospitalisation walk along with inadequate drug therapy and how overall cost effects develop


Ten-year evaluation of the integrated health care model ‘Gesundes Kinzigtal’ (Healthy Kinzigtal): start up and consolidation phase (INTEGRAL)

Project leader:

Contact: Ingrid Köster

Duration: 07/2017 – 06/2019

Funding institution: Innovation Committee of the Federal Joint Committee (G-BA)/h2>

Project description:

Patients often experience interface problems when treated by different specialists and in different health care sectors. Integrated care concepts aim to reduce these problems. While most integrated health care models focus on individual diseases, the integrated care model ’Gesundes Kinzigtal’ applies a population-based approach and addresses the full spectrum of morbidities for a population defined by area of residence – the Kinzigtal. A special feature of the model is the joint savings contract between the regional management company and the statutory health insurers. The INTEGRAL evaluation study aims at assessing the effectiveness of the ‘Gesundes Kinzigtal’ model under routine conditions in comparison to conventional care over a period of 10 years in order to understand the benefits but also the potential for (unintended) harm to health.

The study is based on claims data from statutory health insurance funds 2005-2015. The evaluation consists of a quasi-experimental study, with Kinzigtal as intervention region, at least 10 further regions with a similar population and health care infrastructure as primary controls, and an additional random sample of insurees from the federal state of Baden-Wuerttemberg as secondary controls. Model-specific and ’non-specific’ indicators, adopted from the literature and enriched by focus group interviews will be used to evaluate the model’s effectiveness and potential unintended consequences by analysing health care utilisation in general. Temporal trends per indicator in the intervention region will be compared to those in each control region. Their variation across regions provides information on whether differences between local health care systems can potentially modify an indicator.

The study will provide valuable information for the set up of selective contracts for integrated care and for the further development of the health care system. Besides, the indicators developed for this project can be used for monitoring quality of care in other care systems.

The study is funded for two years with 528.000 Euro.


Evaluation of specialized outpatient palliative care (APVEL)

project leader: Prof. Dr. R. Rolke (University hospital Aachen) with consortium partners University Cologne (PMV forschungsgruppe), University hospital Cologne, University hospital Bonn

Contact: Ingo Meyer

Duration: 06/2017 – 05/2019

Funding institution: Innovation Committee of the Federal Joint Committee (G-BA)

Project description:

German outpatient palliative care is divided into general outpatient palliative care (AAPV) and specialized outpatient palliative care (SAPV). Both forms enable ill and dying persons to spend their remaining time at home so that they can die in a familiar environment. The aim of outpatient palliative care is to provide an increase in quality of life and support patients and their relatives to preserve their self-determination. Additional goals are the alleviation of symptoms such as the reduction of pain. SAPV is based on high standards in providing care and requires an interdisciplinary approach. Therefore, physicians exclusively prescribe SAPV to patients with a complex symptomatology.

The chairs of palliative medicine of Aachen, Bonn, and Cologne aim to evaluate SAPV in the Province of North Rhine. The project contrasts SAPV with AAPV. There are three main research goals. The first part deals with the analysis of administrative health insurance data. So it is focused on patient characteristics and health care tracks as well as health care differences between patients that receive AAPV or SAPV. The second section examines SAPV and AAPV from the patient’s point of view as well as from the perspective of their relatives and palliative care providers.

The third part of the project is located in the Institute of Medical Sociology, Health Services Research, and Rehabilitation Science (IMVR). The institute investigates distinctive features of SAPV and AAPV according to the opinion of general practitioner and oncologists in the outpatient sector. The design of the study is based on mixed methods.


ADVOCATE – Added Value for Oral Care

Project leader Work Package 3: Prof. Dr. Dr. S. Listl

contact: Dr. Jutta Küpper-Nybelen

Duration: 05/2015 - 04/2019

Funding institution: EU - Horizon 2020

Project description:

 


Rehabilitative health care for geriatric patients in Baden-Württemberg

Project leader:

Contact: Ingrid Köster, Dr. Ingrid Schubert

Duration: 04/2016 - 10/2018

Funding institution:

Project description:

 


BARMER drug report 2017, main theme medical tumor therapy

Project leader:

Contact: Dr. Veronika Lappe

Duration: 12/2017 – 05/2018

Funding institution: BARMER

Project description:

 


Report on the health and social situation of children and adolescents in Brandenburg

Project leader: Dr. Ingrid Schubert

Contact: Katja Blaschke, Ingrid Schubert

Duration: 09/2017 – 03/2018

Funding institution:

Project description:

 


Comparative analysis of the incidence of cardiovascular events of patients with prostate cancer – A retrospective observational study based on anonymized GKV routine data (Modul 1)

Project leader: Peter Ihle

Contact: Peter Ihle

Duration: 12/2016 – 12/2017

Funding institution: Ferring GmbH

Project description:

 


Bleeding events and ischemic strokes of patients with auricular fibrillation under direct oral anticoagulants versus under phenprocoumon

Project leader:

Contact: Dr. R. Hein

Duration: 06/2015 - 04/2017

Funding institution: AOK Bundesverband

Project description:

 


Comparative analysis regarding the adherence of patients with cardiac insufficiency

Project leader: Peter Ihle

Contact: Peter Ihle

Duration: 04/2016 - 01/2017

Funding institution: ABDA – Bundesvereinigung Deutscher Apothekerverbände

Project description:

 


Prescription development of combined hormonal contraceptives before and after the EMA referral process 2013/2014. An analysis on nationwide health insurance data for the period from 08/2010 to 07/2015

Project leader:

Contact: Dr. Ingrid Schubert

Duration: 04/2016 - 01/2017

Funding institution:

Project description:

 


Evaluation of the contract for integrated care on psycho-oncological care of patients with cancer in the region of Aachen

Project leader: Dr. Ingrid Schubert

Contact: Dr. Veronika Lappe

Duration: 07/2016 - 09/2016

Funding institution: AOK Rheinland/Hamburg

 


BARMER GEK Arzneimittelreport 2016: Biotechnologically manufactured medicinal products

Project leader data analysis: Dr. Ingrid Schubert

Contact: Dr. Veronika Lappe, Frau Dr. Jutta Küpper-Nybelen

Duration: 12/2015 - 05/2016

Funding institution: Barmer GEK

 


Premature birth and premature labor in pregnancy: morbidity, use and cost of medical care for children and mothers

Project leader: Dr. S. Abbas, Frau Dr. Veronika Lappe

Contact: Dr. S. Abbas, Ingrid Köster

Duration: 05/2015 - 04/2016

Funding institution: Evidera and GlaxoSmithKline GmbH & Co. KG

 


Regional health care networks in the area around Gießen / Small-scare care analysis with an indicator set for insured persons with dementia diseases in the district of Gießen

Project leader: Peter Ihle

Contact: Dr. Veronika Lappe

Duration: 04/2015 - 12/2015

Funding institution:

 


Psychotropic drugs for children and adolescents: Temporal trend, long-term courses and influencing factors for a prescription bases on data from Germany-wide operating health insurances

Project leader:

Contact: Dr. S. Abbas, Herr Peter Ihle

Duration: 02/2012 - 07/2015

Funding institution:

 


Investigation for recording the severity level in routine data for selected diagnoses: Literature overview and routine data analysis on different operationalizations and their evaluation

Project leader: Dr. Ingrid Schubert

Contact: Dr. Ingrid Schubert, Ingrid Köster

Duration: 07/2014 - 06/2015

Funding institution:

 


Pilot project for operationalization and frequency estimation of statin intolerance

Project leader: Peter Ihle

Contact: Peter Ihle

Duration: 12/2014 - 03/2015

Funding institution: Sanofi-Aventis Deutschland GmbH

 


Bavarian Child Health Report

Project leader: Dr. Ingrid Schubert

Contact: Dr. Ingrid Schubert

Duration: 11/2014 - 03/2015

Funding institution:

 


Multimedication for elderly patients with (outpatient) care (MuPP)

Project leader: Dr. Ingrid Schubert

Contact: Frau Dr. Veronika Lappe

Duration: 04/2014 - 02/2015

Funding institution:

 


Epidemiogical care study on breast cancer with focus on drug therapy

Project leader: Dr. Ingrid Schubert

Ansprechpartner: Dr. R. Hein

Duration: 03/2014 - 02/2015

Funding institution: Roche Pharma AG

 


Epidemiology and care of patients with chronic wounds

Project leader: Dr. Ingrid Schubert

Contact: Ingrid Köster

Duration: 10/2014 - 01/2015

Funding institution:

 


Accompanying research on Franziskus-Carré

Project leader: Dr. Ingrid Schubert

Ansprechpartner:

Duration: 03/2014 - 01/2015

Funding institution: Franziskus Hospital Münster

 


Observation of the use of incidence / relapsed patients with Crohn’s disease and ulcerative colitis

Project leader: Dr. Ingrid Schubert

Contact: Dr. R. Hein, Dr. Ingrid Schubert

Duration: 07/2014 - 10/2014

Funding institution: AbbVie Deutschland GmbH & Co. KG

 


Epidemiology, care and cost estimation for patients with Crohn’s disease and ulcerative colitis

Project leader: Dr. Ingrid Schubert

Contact: Dr. R. Hein

Duration: 03/2014 - 07/2014

 


Diabetes barometer

Project leader: Dr. Ingrid Schubert

Contact: Ingrid Köster

Duration: 03/2009 - 03/2014

Funding institution: Novo Nordisk Pharma GmbH

 


Arthritis: Patient characteristic, use, sickness costs and treatment patterns

Project leader: Dr. Ingrid Schubert

Contact: Dr. R. Hein

Duration: 02/2013 - 01/2014

Funding institution: Evidera